Published in Cancer on November 15, 2009
Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology (2013) 0.94
Erythropoietin is involved in angiogenesis in human primary melanoma. Int J Exp Pathol (2010) 0.79
Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. Invest New Drugs (2013) 0.76
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs (2013) 0.75
Angiogenesis and melanoma. Cancers (Basel) (2010) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Management of cutaneous melanoma. N Engl J Med (2004) 9.52
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med (2007) 8.77
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res (2005) 6.66
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol (2009) 3.41
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood (2007) 2.80
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol (2008) 2.79
Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol (2008) 2.79
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer (2010) 2.73
Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol (2013) 2.71
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol (2002) 2.52
Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol (2011) 2.45
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med (2011) 2.34
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist (2008) 2.22
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol (2007) 2.19
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer (2014) 2.12
Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings. Radiology (2009) 2.08
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res (2010) 2.03
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol (2012) 2.02
PD-1 as a potential target in cancer therapy. Cancer Med (2013) 1.98
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res (2005) 1.97
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol (2007) 1.95
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res (2007) 1.92
Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist (2013) 1.91
Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res (2007) 1.84
Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother (2005) 1.78
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (2011) 1.78
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer (2006) 1.75
Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med (2008) 1.69
Hybrid PET-CT simulation for radiation treatment planning in head-and-neck cancers: a brief technical report. Int J Radiat Oncol Biol Phys (2004) 1.68
Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol (2002) 1.65
The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res (2006) 1.65
Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol (2008) 1.60
State of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 1.58
Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin Cancer Res (2007) 1.57
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Ann Surg Oncol (2012) 1.56
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 1.55
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol (2003) 1.49
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. J Immunother (2013) 1.48
Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma. Cancer (2004) 1.47
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol (2009) 1.45
Arterial spin labeling MR imaging for characterisation of renal masses in patients with impaired renal function: initial experience. Eur Radiol (2011) 1.44
Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology (2009) 1.42
The Role of Intralesional Therapies in Melanoma. Oncology (Williston Park) (2016) 1.39
Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma. Clin Cancer Res (2006) 1.35
A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid (2009) 1.35
New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol (2003) 1.34
Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol (2008) 1.33
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One (2011) 1.32
Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther (2006) 1.32
The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res (2007) 1.31
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res (2009) 1.30
Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer (2004) 1.30
Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther (2004) 1.29
Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park) (2014) 1.29
Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol (2007) 1.26
Tfap2 transcription factors in zebrafish neural crest development and ectodermal evolution. J Exp Zool B Mol Dev Evol (2007) 1.24
Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res (2013) 1.23
Survival and pattern of failure in brain metastasis treated with stereotactic gamma knife radiosurgery. J Neurosurg (2002) 1.22
GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem (2007) 1.21
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res (2010) 1.19
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica (2010) 1.18
Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother (2012) 1.18
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun (2013) 1.17
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer (2009) 1.15
Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. Radiology (2007) 1.13
Rapid development of hypertension by sorafenib: toxicity or target? Clin Cancer Res (2009) 1.12
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res (2012) 1.11
Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol (2010) 1.11
Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer (2006) 1.10
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther (2010) 1.10
Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol (2009) 1.10
Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother (2007) 1.10
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol (2012) 1.09
Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys (2002) 1.07
Tissue-based research in kidney cancer: current challenges and future directions. Clin Cancer Res (2008) 1.07